An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A trial of the ECOG-ACRIN Cancer Research Group (E2204)

OBJECTIVES: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely-resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). METHODS: Patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncology
Main Authors: Berlin, Jordan D., Feng, Yang, Catalano, Paul, Abbruzzese, James L., Philip, Philip A., McWilliams, Robert R., Lowy, Andrew M., Benson, Al B., Blackstock, A. William
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5828967/
https://ncbi.nlm.nih.gov/pubmed/29040974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000480295
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados